A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department

被引:204
作者
Borland, Meredith
Jacobs, Ian
King, Barbara
O'Brien, Debra
机构
[1] Princess Margaret Hosp Children, Subiaco, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia
[3] Univ Western Australia, Discipline Emergency Med, Perth, WA 6009, Australia
[4] Sir Charles Gairdner Hosp, Emergency Dept, Nedlands, WA, Australia
关键词
D O I
10.1016/j.annemergmed.2006.06.016
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: We compare the efficacy of intranasal fentanyl versus intravenous morphine in a pediatric population presenting to an emergency department (ED) with acute long-bone fractures. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, clinical trial in a tertiary pediatric ED between September 2001 and January 2005. A convenience sample of children aged 7 to 15 years with clinically deformed closed long-bone fractures was included to receive either active intravenous morphine (10 mg/mL) and intranasal placebo or active intranasal concentrated fentanyl (150 mu g/mL) and intravenous placebo. Exclusion criteria were narcotic analgesia within 4 hours of arrival, significant head injury, allergy to opiates, nasal blockage, or inability to per-form pain scoring. Pain scores were rated by using a 100-mm visual analog scale at 0, 5, 10, 20, and 30 minutes. Routine clinical observations and adverse events were recorded. Results: Sixty-seven children were enrolled (mean age 10.9 years [SD 2.4]). Fractures were radius or ulna 53 (79.1%), humerus 9 (13.4%), tibia or fibula 4 (6.0%), and femur 1 (1.5%). Thirty-four children received intravenous (IV) morphine and 33 received intranasal fentanyl. Statistically significant differences in visual analog scale scores were not observed between the 2 treatment arms either preanalgesia or at 5, 10, 20, or 30 minutes postanalgesia (P=.333). At 10 minutes, the difference in mean visual analog scale between the morphine and fentanyl groups was -5 mm (95% confidence interval -16 to 7 mm). Reductions in combined pain scores occurred at 5 minutes (20 mm; P=.000), 10 minutes (4 mm; P=.012), and 20 minutes (8 mm; P=.000) postanalgesia. The mean total INF dose was 1.7 mu g/kg, and the mean total IV morphine dose was 0.11 mg/kg. There were no serious adverse events. Conclusion: Intranasal fentanyl delivered as 150 mu g/mL at a dose of 1.7 mu g/kg was shown to be an effective analgesic in children aged 7 to 15 years presenting to an ED with an acute fracture when compared to intravenous morphine at 0.1 mg/kg.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 22 条
[1]  
[Anonymous], 1999, Emerg Med
[2]  
Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x
[3]   Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: A randomised double blind crossover study [J].
Borland, ML ;
Bergesio, R ;
Pascoe, EM ;
Turner, S ;
Woodger, S .
BURNS, 2005, 31 (07) :831-837
[4]  
Brent ASG, 2000, PEDIATR CLIN N AM, V47, P651
[5]  
*COMM AUSTR CANB, 1999, NHMRC GUID ETH RES
[6]   A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns [J].
Finn, J ;
Wright, J ;
Fong, J ;
Mackenzie, E ;
Wood, F ;
Leslie, G ;
Gelavis, A .
BURNS, 2004, 30 (03) :262-268
[7]   Pediatric emergency department analgesic practice [J].
Friedland, LR ;
Pancioli, AM ;
Duncan, KM .
PEDIATRIC EMERGENCY CARE, 1997, 13 (02) :103-106
[8]   Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia [J].
Galinkin, JL ;
Fazi, LM ;
Cuy, RM ;
Chiavacci, RM ;
Kurth, CD ;
Shah, UK ;
Jacobs, IN ;
Watcha, MF .
ANESTHESIOLOGY, 2000, 93 (06) :1378-1383
[9]   Review of pain-measurement tools [J].
Ho, K ;
Spence, J ;
Murphy, MF .
ANNALS OF EMERGENCY MEDICINE, 1996, 27 (04) :427-432
[10]  
Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x